CD19 and diffuse large B-cell lymphoma: Thus far, CAR T cells have proven to be effective in the setting of relapsed/refractory, CD19-expressing B cell malignancies such as acute lymphoblastic leukemia (ALL) and diffuse large B cell lymphoma (DLBCL) [58].